ivWatch Grows Global Intellectual Property Portfolio with Additional Patent Grants


As of December 2018 Australian and Japanese patent grants bring ivWatch owned patents to nine

HAMPTON, Va., December 5, 2018 – ivWatch, the only provider of continuous monitoring devices for the early detection of intravenous (IV) infiltrations and extravasations, recently had two patent applications granted by the Australian and Japanese Patent Offices expanding the company’s intellectual property (IP) portfolio. ivWatch now owns nine patents around the world corresponding to their proprietary breakthrough technologies.

The granting of Australian Patent No. 2013257212 is for a technology regarding how an ivWatch sensor head adheres to and is secured on a patient’s skin. These appliances, known as receptacles, can be independent of the dressings that cover infusion sites during IV therapy or integrated within. This Australian grant comes on the heels of the company announcing an Australia and New Zealand distribution agreement with New Medical, a supplier of medical consumables, devices and patient monitoring accessories.

“Our research and development efforts allow us to continually innovate,” said Gary Warren, president and CEO of ivWatch. “Protecting the resulting breakthroughs of those efforts as we expand into new markets ensures patients have highly effective early detection technology no matter where they are receiving medical treatment.”

ivWatch patented technology addresses patient harm caused by peripheral IV infiltration and extravasation events head-on, something many medical device companies and health care systems have attempted over the past 30 years. ivWatch succeeded by solving motion issues related to continuous peripheral IV therapy monitoring.

This core technology is related to ivWatch’s fourth Japanese patent grant, Registration No. 6396904, for mitigating the effects of tissue blood volume changes. This patent describes methods used by ivWatch to extract meaningful signals from biosensors where patient motion produces unwanted noise. By mitigating the effects of changing tissue blood volume, the system minimizes “false” notifications. Reliable early detection of these events paves the way for a new standard of care to minimize injuries associated with the common complication of IV therapy.

To learn more about ivWatch, visit ivwatch.com.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLCivwatch.com

Erin Wendell
Mobile (757) 633-4688